Minimal residual disease in acute myeloid leukemia: already predicting a safe haven?

References

• Bene MC, Kaeda JS. How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet. Haematologica94(8), 1135–1150 (2009).
   PubMed Web of Science ®Google Scholar
• Schrappe M, Beier R, Burger B. New treatment strategies in childhood acute lymphoblastic leukaemia. Best. Pract. Res. Clin. Haematol.15(4), 729–740 (2002).
   PubMed Web of Science ®Google Scholar
• Cazzaniga G, Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica90(3), 382–390 (2005).
   PubMed Web of Science ®Google Scholar
• Feller N, van der Pol MA, van Stijn A et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia18(8), 1380–1390 (2004).
   PubMed Web of Science ®Google Scholar
• Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood104(10), 3078–3085 (2004).
   PubMed Web of Science ®Google Scholar
• Langebrake C, Creutzig U, Dworzak M et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD–AML–BFM study group. J. Clin. Oncol.24(22), 3686–3692 (2006).
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Martinez A, Macedo A et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood90(6), 2465–2470 (1997).
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Vidriales MB, Lopez-Berges C et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood98(6), 1746–1751 (2001).
   PubMed Web of Science ®Google Scholar
• Venditti A, Buccisano F, Del Poeta G et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood96(12), 3948–3952 (2000).
   PubMed Web of Science ®Google Scholar
• Sievers EL, Lange BJ, Alonzo TA et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children’s Cancer Group study of 252 patients with acute myeloid leukemia. Blood101(9), 3398–3406 (2003).
   PubMed Web of Science ®Google Scholar
• Maurillo L, Buccisano F, Del Principe MI et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J. Clin. Oncol.26(30), 4944–4951 (2008).
   PubMed Web of Science ®Google Scholar
• Schnittger S, Kern W, Tschulik C et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood114(11), 2220–2231 (2009).
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Gaipa G, Ratei R et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multicentric assessment is feasible. Cytometry B Clin. Cytom.74(6), 331–340 (2008).
   PubMed Web of Science ®Google Scholar
• Cloos J, Goemans BF, Hess CJ et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia20(7), 1217–1220 (2006).
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood100(7), 2393–2398 (2002).
   PubMed Web of Science ®Google Scholar
• Bachas C, Schuurhuis GJ, Hollink IHIM et al. Frequent instability of type I and II aberrations between diagnosis and relapse observed in pediatric AML; implications for targeted therapy and MRD detection. Blood114, 649 (2009).
   Google Scholar
• Gorello P, Cazzaniga G, Alberti F et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia20(6), 1103–1108 (2006).
   PubMed Web of Science ®Google Scholar
• Chou WC, Tang JL, Wu SJ et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia21(5), 998–1004 (2007).
   PubMed Web of Science ®Google Scholar
• Kern W, Haferlach C, Bacher U, Haferlach T, Schnittger S. Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity. Leukemia23(7), 1361–1364 (2009).
   PubMed Web of Science ®Google Scholar
• Cilloni D, Renneville A, Hermitte F et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J. Clin. Oncol.27(31), 5195–5201 (2009).
   PubMed Web of Science ®Google Scholar
• Tajeddine N, Millard I, Gailly P, Gala JL. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin. Chem. Lab. Med.44(5), 548–555 (2006).
   PubMed Web of Science ®Google Scholar
• Steinbach D, Schramm A, Eggert A et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin. Cancer Res.12(8), 2434–2441 (2006).
   PubMed Web of Science ®Google Scholar
• Pedreira CE, Costa ES, Barrena S et al. Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry A73(9), 834–846 (2008).
   PubMedGoogle Scholar
• van der Velden VHJ, Jacobs DCH, Wijkhuijs AJM et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia16(8), 1432–1436 (2002).
   PubMed Web of Science ®Google Scholar
• Maurillo L, Buccisano F, Spagnoli A et al. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica92(5), 605–611 (2007).
   PubMed Web of Science ®Google Scholar
• Kern W, Haferlach T, Schoch C et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative group (AMLCG) 1992 Trial. Blood101(1), 64–70 (2003).
   PubMed Web of Science ®Google Scholar
• van Rhenen A, Feller N, Kelder A et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res.11(18), 6520–6527 (2005).
   PubMed Web of Science ®Google Scholar
• Terwijn M, Kelder A, Rutten AP, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ. High leukemic cell frequency in remission bone marrow predicts poor outcome in acute myeloid leukemia. Blood112, 881 (2008).
   Google Scholar
• Terwijn M, Kelder A, Rutten AP et al. Specific flow cytometric detection of leukemic stem cells in acute myeloid leukemia predicts prognosis in remission bone marrow. Blood114, 165 (2009).
   PubMedGoogle Scholar
• Krause DS, Van Etten RA. Right on target: eradicating leukemic stem cells. Trends Mol. Med.13(11), 470–481 (2007).
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell138(2), 286–299 (2009).
   PubMed Web of Science ®Google Scholar